Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

PURPOSE: Buparlisib, an oral reversible inhibitor of all class I phosphoinositide-3-kinases, has shown antitumoral activity against estrogen receptor (ER)-positive breast cancer cell lines and xenografts, alone and with endocrine therapy. This phase Ib study evaluated buparlisib plus letrozole'...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Mayer, Ingrid A., Abramson, Vandana G., Isakoff, Steven J., Forero, Andres, Balko, Justin M., Kuba, María Gabriela, Sanders, Melinda E., Yap, Jeffrey T., Van den Abbeele, Annick D., Li, Yisheng, Cantley, Lewis C., Winer, Eric, Arteaga, Carlos L.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2014
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3986383/
https://ncbi.nlm.nih.gov/pubmed/24663045
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.54.0518
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados